Journal of the American Heart Association · 2025
Prior Dual Antiplatelet Therapy and Mortality After Intracerebral Hemorrhage: A Danish Nationwide Cohort Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ovesen Christian, García Rodríguez Luis Alberto, Hallas Jesper, Storm Camilla, Hald Stine Munk, Möller Sören, Selim Magdy, Gaist David
Аннотация
BACKGROUND: Limited data support the link between dual antiplatelet therapy (DAPT) and adverse outcome among patients with intracerebral hemorrhage. This study aimed to investigate the association between prior use of DAPT and mortality after intracerebral hemorrhage.
METHODS: Patients with first-ever intracerebral hemorrhage on current APT at the time of admission, were identified and followed 180 days after admission through the Danish nationwide registries. Prior exposure to DAPT or single APT (SAPT) was established through the Danish National Prescription Registry. Inverse probability of treatment weighting was used to control for confounding.
RESULTS: A total of 5800 patients were on antiplatelet therapy. 5535 (95.4%) were on SAPT, and 265 (4.6%) were on DAPT. Compared with patients on SAPT, patients on DAPT more commonly had a history of ischemic stroke or transient ischemic attack (134 [50.6%] versus 2393 [43.2%]), ischemic heart disease (172 [64.9%] versus 1561 [28.2%]), congestive heart failure (57 [21.5%] versus 505 [9.1%]) or chronic kidney disease (25 [9.4%] versus 205 [3.7%]). The 180-day cumulative mortality rate was 52.6% for patients on DAPT and 45.6% for patients on SAPT (P=0.004). After weighting and compared with SAPT, prior use of DAPT was associated with a 43% higher mortality risk at day 1 (weighted risk ratio 1.43, 95% CI, 1.13-1.82). Higher early mortality among patients on DAPT was found to be the driving force behind the higher day 180 mortality in this group.
CONCLUSIONS: Among patients with intracerebral hemorrhage, prior DAPT was found to be associated with a higher mortality compared with SAPT.
METHODS: Patients with first-ever intracerebral hemorrhage on current APT at the time of admission, were identified and followed 180 days after admission through the Danish nationwide registries. Prior exposure to DAPT or single APT (SAPT) was established through the Danish National Prescription Registry. Inverse probability of treatment weighting was used to control for confounding.
RESULTS: A total of 5800 patients were on antiplatelet therapy. 5535 (95.4%) were on SAPT, and 265 (4.6%) were on DAPT. Compared with patients on SAPT, patients on DAPT more commonly had a history of ischemic stroke or transient ischemic attack (134 [50.6%] versus 2393 [43.2%]), ischemic heart disease (172 [64.9%] versus 1561 [28.2%]), congestive heart failure (57 [21.5%] versus 505 [9.1%]) or chronic kidney disease (25 [9.4%] versus 205 [3.7%]). The 180-day cumulative mortality rate was 52.6% for patients on DAPT and 45.6% for patients on SAPT (P=0.004). After weighting and compared with SAPT, prior use of DAPT was associated with a 43% higher mortality risk at day 1 (weighted risk ratio 1.43, 95% CI, 1.13-1.82). Higher early mortality among patients on DAPT was found to be the driving force behind the higher day 180 mortality in this group.
CONCLUSIONS: Among patients with intracerebral hemorrhage, prior DAPT was found to be associated with a higher mortality compared with SAPT.